GHK-Cu
Naturally occurring copper-binding tripeptide studied in skin and tissue biology.
Editorial review: August 13, 2026Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
GHK-Cu has no NDA or BLA. Cosmetic INCI listing is not an approved indication. Off-label does not apply. There is no drug label to be off of.
Bottom line
Two small topical human trials exist (diabetic plantar ulcers; post-laser facial skin, n=13). The rest of this set is mice, cells, zebrafish, a carrier-microsphere paper, or measurement of endogenous plasma GHK — which is not GHK-Cu treatment. Do not read a COPD plasma-GHK correlation as a GHK-Cu intervention in people.
Papers
Early human
PMID 17147644 — Mulder 1994
Tested: multicenter randomized, evaluator-blinded, vehicle-controlled trial of topical GHK-Cu on diabetic neuropathic plantar ulcers, on top of standardized wound care.
Does not show: an effect of injected or oral GHK-Cu, a non-ulcer use, or a modern drug approval.
PMID 16847171 — Miller 2006
Tested: randomized post-CO2-laser facial care with or without topical GHK-Cu, n=13. Computer scoring and blinded evaluators found no significant difference in erythema resolution; wrinkle and overall appearance scores also did not differ between groups. A patient questionnaire favored GHK-Cu on overall skin quality.
Does not show: a robust, rater-confirmed effect. n=13.
Preclinical
Tested: plasma GHK (not GHK-Cu treatment) in 9 people with COPD versus 11 controls; GHK-Cu was then given to C2C12 myotubes and to cigarette-smoke-exposed mice.
Does not show: that giving GHK-Cu to people changes muscle function. The human arm is an endogenous peptide level, a different object.
Tested: GHK-Cu in a cigarette-smoke mouse emphysema and inflammation model.
Does not show: a human lung result.
Tested: GHK-Cu loaded on injectable hydroxyapatite microspheres in laboratory / anti-inflammatory and antioxidant assays.
Does not show: a human filler or injection trial.
Tested: GHK-Cu in zebrafish larvae inflammation models.
Does not show: a human result.
PMID 22937864 — Campbell 2012
Tested: gene expression across emphysema-severity regions in human COPD lung tissue; GHK applied to fibroblasts in vitro as a reversal signature.
Does not show: GHK-Cu treatment of people with COPD. Tissue profiling plus a cell experiment.
Context, not a grade
PMID 26236730, 29986520 — Pickart reviews of GHK / GHK-Cu pathways. PMID 35083444 — commentary on GHK as an aging peptide. PMID 39963574 — cosmetic review; notes a paucity of GHK-Cu clinical studies. These are not additional trials.
What is not established
A drug-approved use. Systemic GHK-Cu in people. COPD, emphysema, silicosis, colitis, or “anti-aging” as human treatment claims. Cosmetic listing is not a substitute for an approved indication.
Selected sources
17147644 16847171 36905132 35936787 38879894 40672369 40716276 41997403 22937864 26236730 29986520 35083444 39963574
Reported experiences
Skin, hair, recovery
Reported topics are not established benefits.Risks and unknowns
Skin irritation, copper exposure concerns, formulation and sterility uncertainty
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.